Harty G - Search Results

1

Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.

Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, Wong SL. Siddiqui MK, et al. Among authors: harty g. Curr Med Res Opin. 2018 Aug;34(8):1361-1371. doi: 10.1080/03007995.2017.1407303. Epub 2017 Nov 28. Curr Med Res Opin. 2018. PMID: 29149804

2

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.

Hettle R, Harty G, Wong SL. Hettle R, et al. Among authors: harty g. J Med Econ. 2018 Jul;21(7):676-686. doi: 10.1080/13696998.2018.1461630. Epub 2018 Apr 16. J Med Econ. 2018. PMID: 29618273 Free article.

3

Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.

Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL. Berardi A, et al. Among authors: harty g. Curr Med Res Opin. 2019 Aug;35(8):1371-1378. doi: 10.1080/03007995.2019.1585779. Epub 2019 Mar 29. Curr Med Res Opin. 2019. PMID: 30786783

4

Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.

Gorrod HB, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL. Gorrod HB, et al. Value Health. 2019 Jul;22(7):772-776. doi: 10.1016/j.jval.2018.11.015. Epub 2019 May 17. Value Health. 2019. PMID: 31277823 Free article. Clinical Trial.

5

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.

Michels RE, de Fransesco M, Mahajan K, Hengstman GJD, Schiffers KMH, Budhia S, Harty G, Krol M. Michels RE, et al. Among authors: harty g. Appl Health Econ Health Policy. 2019 Dec;17(6):857-873. doi: 10.1007/s40258-019-00500-8. Appl Health Econ Health Policy. 2019. PMID: 31444659 Free PMC article.

6

Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.

Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL. Bell Gorrod H, et al. Adv Ther. 2020 Jan;37(1):225-239. doi: 10.1007/s12325-019-01140-z. Epub 2019 Nov 7. Adv Ther. 2020. PMID: 31701485 Clinical Trial.

7

Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.

Michels RE, De Francesco M, Mahajan K, Hengstman GJD, Schiffers KMH, Budhia S, Harty G, Krol M. Michels RE, et al. Among authors: harty g. Appl Health Econ Health Policy. 2020 Feb;18(1):141. doi: 10.1007/s40258-019-00548-6. Appl Health Econ Health Policy. 2020. PMID: 31939112 Free PMC article.

8

Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.

Jonker MF, Donkers B, Goossens LMA, Hoefman RJ, Jabbarian LJ, de Bekker-Grob EW, Versteegh MM, Harty G, Wong SL. Jonker MF, et al. Among authors: harty g. Med Decis Making. 2020 Feb;40(2):198-211. doi: 10.1177/0272989X19897944. Epub 2020 Feb 17. Med Decis Making. 2020. PMID: 32065023

9

Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review.

Siddiqui MK, Singh B, Attri S, Veraart C, Harty G, Wong SL. Siddiqui MK, et al. Among authors: harty g. Curr Med Res Opin. 2020 May;36(5):809-826. doi: 10.1080/03007995.2020.1739009. Epub 2020 Mar 20. Curr Med Res Opin. 2020. PMID: 32129684

10

Modified Delphi study of decision-making around treatment sequencing in relapsing-remitting multiple sclerosis.

Piena MA, Schoeman O, Palace J, Duddy M, Harty GT, Wong SL. Piena MA, et al. Among authors: harty gt. Eur J Neurol. 2020 Aug;27(8):1530-1536. doi: 10.1111/ene.14267. Epub 2020 May 20. Eur J Neurol. 2020. PMID: 32302441

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters